All In Biotech

Drugs by condition

Drugs approved for pulmonary arterial hypertension

Brand-name prescription drugs and biologics whose FDA label lists pulmonary arterial hypertension as an approved use. Matched on the label phrases: "pulmonary arterial hypertension".

Last checked: Nov 20, 2026Source: FDA labels (openFDA), Drugs@FDAMethods & limitations

Brand-name drugs approved

19

Still marketed, NDA or BLA

Drug classes

6

Novel drugs

7

New molecular entities and new biologics

In development

11

Investigational drugs in Phase 2 or 3

Newest approvals

The most recently first-approved brand-name drugs for pulmonary arterial hypertension.

  • Yutrepia (Treprostinil Sodium) · Liquidia Tech May 23, 2025
  • Winrevair (Sotatercept-Csrk) · Merck Sharp Dohme NovelBreakthrough therapyPriority reviewOrphanMar 26, 2024
  • Opsynvi (Macitentan, Tadalafil) · Actelion OrphanMar 22, 2024
  • Tadliq (Tadalafil) · Cmp Dev LLC Jun 17, 2022
  • Tyvaso Dpi (Treprostinil) · United Therap Priority reviewOrphanMay 23, 2022

All approved drugs for pulmonary arterial hypertension, by class

Every marketed NDA or BLA whose current FDA label names this condition in its Indications and Usage section, plus 66 generic labels. A drug can be approved for only part of a condition (one subtype or stage, or as add-on therapy), so check its label.

Prostacycline Vasodilator (5)

  • Remodulin Treprostinil · United Therap · 2002
  • Tyvaso Dpi Treprostinil · United Therap · 2022
  • Orenitram Treprostinil Diolamine · United Therap · 2013
  • Tyvaso Treprostinil · United Therap · 2009
  • Veletri Epoprostenol Sodium · Actelion · 2008

Phosphodiesterase 5 Inhibitor (3)

  • Opsynvi Macitentan, Tadalafil · Actelion · 2024
  • Tadliq Tadalafil · Cmp Dev LLC · 2022
  • Adcirca Tadalafil · Eli Lilly CO · 2009

Prostacyclin Receptor Agonist (2)

  • Uptravi Selexipag · Actelion · 2015
  • Uptravi Selexipag · Actelion · 2021

Endothelin Receptor Antagonist (2)

  • Opsumit Macitentan · Actelion · 2013
  • Letairis Ambrisentan · Gilead · 2007

Soluble Guanylate Cyclase Stimulator (1)

  • Adempas Riociguat · Bayer Hlthcare · 2013

Class not listed in FDA's data (6)

  • Winrevair Sotatercept-Csrk · Merck Sharp Dohme · 2024
  • Tracleer Bosentan · Actelion · 2001
  • Yutrepia Treprostinil Sodium · Liquidia Tech · 2025
  • Tracleer Bosentan · Actelion · 2017
  • Revatio Sildenafil Citrate · Viatris · 2009
  • Revatio Sildenafil Citrate · Viatris · 2005

Drugs in development for pulmonary arterial hypertension

Investigational drugs FDA has not approved, in active or recent industry-sponsored Phase 2 and 3 trials for this condition. Phase 3 first.

Search the pipeline
  • INS1009Treprostinil PalmitilPhase 37 trials

    Insmed Incorporated · Interstitial Lung Disease, Pulmonary Hypertension, Pulmonary Arterial Hypertension

  • IKT-001Phase 32 trials

    Inhibikase Therapeutics · Pulmonary Arterial Hypertension, Pulmonary Arterial Hypertension (PAH)

  • RalinepagAPD811Phase 32 trials

    United Therapeutics · PAH, Pulmonary Hypertension, Pulmonary Arterial Hypertension

  • SeralutinibPhase 32 trials

    Gossamer Bio USA, Inc. · Pulmonary Arterial Hypertension

  • HS235Phase 22 trials

    35Pharma Inc., a GSK company · Pulmonary Arterial Hypertension, Pulmonary Hypertension, Heart Failure With Preserved Ejection Fraction

  • NS-863Phase 22 trials

    NS Pharma, Inc. · Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD), Pulmonary Arterial Hypertension

  • APL-9796Phase 21 trial

    Apollo Therapeutics Ltd · Pulmonary Arterial Hypertension

  • DIAG723Phase 21 trial

    Diagonal Therapeutics, Inc. · Hereditary Hemorrhagic Telangiectasia, Pulmonary Arterial Hypertension

  • PF-07868489Phase 21 trial

    Pfizer · Pulmonary Arterial Hypertension

  • REGN13335Phase 21 trial

    Regeneron · Pulmonary Arterial Hypertension (PAH)

  • ROC-101Phase 21 trial

    AllRock Bio, Inc. · Pulmonary Arterial Hypertension (PAH), Pulmonary Hypertension, Interstitial Lung Disease

1 discontinued brand-name drugs whose label still names it

More on pulmonary arterial hypertension: recruiting trials · published research

Related in respiratory: Asthma · COPD · Cystic fibrosis · Idiopathic pulmonary fibrosis · Allergies (allergic rhinitis)

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.